Do analysts rate RENX or COG?

Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 106.95%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer INHC or COG?

Cambridge Cognition has a consensus price target of GBX 56, suggesting a potential upside of 106.95%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Induction Healthcare Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Induction Healthcare Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend COG or FDBK?

Cambridge Cognition presently has a consensus price target of GBX 56, suggesting a potential upside of 106.95%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Feedback. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Feedback 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate IQAI or COG?

Cambridge Cognition has a consensus target price of GBX 56, indicating a potential upside of 106.95%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Cambridge Cognition is more favorable than IQ-AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IQ-AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better earnings & valuation, IQAI or COG?

IQ-AI has higher earnings, but lower revenue than Cambridge Cognition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQ-AI £538.19K 3.30 N/A N/A N/A Cambridge Cognition £9.40M 1.55 -£1.58M -£3.90 N/A

Is IQAI or COG more profitable?

Cambridge Cognition has a net margin of -13.86% compared to IQ-AI's net margin of -77.52%. Cambridge Cognition's return on equity of -54.17% beat IQ-AI's return on equity. Company Net Margins Return on Equity Return on Assets IQ-AI -77.52% -140.75% -22.03% Cambridge Cognition -13.86% -54.17% -0.30%

Do analysts recommend DVRG or COG?

Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 106.95%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Cambridge Cognition is more favorable than DeepVerge. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DeepVerge 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Cambridge Cognition (COG) Competitors

GBX 27.06 -0.44 (-1.60%)

As of 10:49 AM Eastern

Compare

COG vs. RENX, INHC, FDBK, IQAI, and DVRG

Should you buy Cambridge Cognition stock or one of its competitors? Cambridge Cognition's main competitors and comparable companies include Renalytix (RENX), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), and DeepVerge (DVRG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Cambridge Cognition compare to Renalytix?

Renalytix (LON:RENX) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	8.33	-£109.93M	-£4.00	N/A
Cambridge Cognition	£9.40M	1.55	-£1.58M	-£3.90	N/A

In the previous week, Renalytix had 1 more articles in the media than Cambridge Cognition. MarketBeat recorded 2 mentions for Renalytix and 1 mentions for Cambridge Cognition. Renalytix's average media sentiment score of 0.25 beat Cambridge Cognition's score of -0.10 indicating that Renalytix is being referred to more favorably in the media.

Company	Overall Sentiment
Renalytix	Neutral
Cambridge Cognition	Neutral

14.0% of Renalytix shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 5.1% of Renalytix shares are held by insiders. Comparatively, 3.2% of Cambridge Cognition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Renalytix has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, suggesting that its stock price is 19% less volatile than the broader market.

Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 106.95%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cambridge Cognition has a net margin of -13.86% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-506.25%	675.00%	-93.54%
Cambridge Cognition	-13.86%	-54.17%	-0.30%

Summary

Cambridge Cognition beats Renalytix on 9 of the 16 factors compared between the two stocks.

How does Cambridge Cognition compare to Induction Healthcare Group?

Induction Healthcare Group (LON:INHC) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

46.3% of Induction Healthcare Group shares are owned by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are owned by institutional investors. 54.6% of Induction Healthcare Group shares are owned by company insiders. Comparatively, 3.2% of Cambridge Cognition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cambridge Cognition has lower revenue, but higher earnings than Induction Healthcare Group. Cambridge Cognition is trading at a lower price-to-earnings ratio than Induction Healthcare Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A
Cambridge Cognition	£9.40M	1.55	-£1.58M	-£3.90	N/A

In the previous week, Cambridge Cognition had 1 more articles in the media than Induction Healthcare Group. MarketBeat recorded 1 mentions for Cambridge Cognition and 0 mentions for Induction Healthcare Group. Induction Healthcare Group's average media sentiment score of 0.00 beat Cambridge Cognition's score of -0.10 indicating that Induction Healthcare Group is being referred to more favorably in the media.

Company	Overall Sentiment
Induction Healthcare Group	Neutral
Cambridge Cognition	Neutral

Induction Healthcare Group has a beta of -0.41, meaning that its share price is 141% less volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, meaning that its share price is 19% less volatile than the broader market.

Cambridge Cognition has a consensus price target of GBX 56, suggesting a potential upside of 106.95%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Induction Healthcare Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Induction Healthcare Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cambridge Cognition has a net margin of -13.86% compared to Induction Healthcare Group's net margin of -23.86%. Induction Healthcare Group's return on equity of -14.58% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Induction Healthcare Group	-23.86%	-14.58%	-7.32%
Cambridge Cognition	-13.86%	-54.17%	-0.30%

Summary

Cambridge Cognition beats Induction Healthcare Group on 10 of the 16 factors compared between the two stocks.

How does Cambridge Cognition compare to Feedback?

Cambridge Cognition (LON:COG) and Feedback (LON:FDBK) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Cambridge Cognition has a beta of 0.809, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Feedback has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Cambridge Cognition has higher revenue and earnings than Feedback. Cambridge Cognition is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cambridge Cognition	£9.40M	1.55	-£1.58M	-£3.90	N/A
Feedback	£849.62K	3.40	-£10.84M	-£15.74	N/A

Cambridge Cognition has a net margin of -13.86% compared to Feedback's net margin of -845.25%. Cambridge Cognition's return on equity of -54.17% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cambridge Cognition	-13.86%	-54.17%	-0.30%
Feedback	-845.25%	-135.17%	-22.99%

15.9% of Cambridge Cognition shares are owned by institutional investors. Comparatively, 24.8% of Feedback shares are owned by institutional investors. 3.2% of Cambridge Cognition shares are owned by company insiders. Comparatively, 8.0% of Feedback shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cambridge Cognition presently has a consensus price target of GBX 56, suggesting a potential upside of 106.95%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Feedback.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Feedback	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cambridge Cognition and Cambridge Cognition both had 1 articles in the media. Feedback's average media sentiment score of 0.75 beat Cambridge Cognition's score of -0.10 indicating that Feedback is being referred to more favorably in the news media.

Company	Overall Sentiment
Cambridge Cognition	Neutral
Feedback	Positive

Summary

Cambridge Cognition beats Feedback on 10 of the 15 factors compared between the two stocks.

How does Cambridge Cognition compare to IQ-AI?

IQ-AI (LON:IQAI) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

IQ-AI has higher earnings, but lower revenue than Cambridge Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQ-AI	£538.19K	3.30	N/A	N/A	N/A
Cambridge Cognition	£9.40M	1.55	-£1.58M	-£3.90	N/A

IQ-AI has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, meaning that its stock price is 19% less volatile than the broader market.

Cambridge Cognition has a consensus target price of GBX 56, indicating a potential upside of 106.95%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Cambridge Cognition is more favorable than IQ-AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQ-AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cambridge Cognition has a net margin of -13.86% compared to IQ-AI's net margin of -77.52%. Cambridge Cognition's return on equity of -54.17% beat IQ-AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQ-AI	-77.52%	-140.75%	-22.03%
Cambridge Cognition	-13.86%	-54.17%	-0.30%

15.9% of Cambridge Cognition shares are owned by institutional investors. 66.0% of IQ-AI shares are owned by insiders. Comparatively, 3.2% of Cambridge Cognition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cambridge Cognition had 1 more articles in the media than IQ-AI. MarketBeat recorded 1 mentions for Cambridge Cognition and 0 mentions for IQ-AI. IQ-AI's average media sentiment score of 0.00 beat Cambridge Cognition's score of -0.10 indicating that IQ-AI is being referred to more favorably in the media.

Company	Overall Sentiment
IQ-AI	Neutral
Cambridge Cognition	Neutral

Summary

Cambridge Cognition beats IQ-AI on 10 of the 14 factors compared between the two stocks.

How does Cambridge Cognition compare to DeepVerge?

DeepVerge (LON:DVRG) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 106.95%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Cambridge Cognition is more favorable than DeepVerge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DeepVerge	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

DeepVerge has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, indicating that its share price is 19% less volatile than the broader market.

Cambridge Cognition has lower revenue, but higher earnings than DeepVerge. Cambridge Cognition is trading at a lower price-to-earnings ratio than DeepVerge, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DeepVerge	£12.41M	0.00	-£2.46M	-£0.01	N/A
Cambridge Cognition	£9.40M	1.55	-£1.58M	-£3.90	N/A

Cambridge Cognition has a net margin of -13.86% compared to DeepVerge's net margin of -19.81%. DeepVerge's return on equity of -10.27% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DeepVerge	-19.81%	-10.27%	-5.56%
Cambridge Cognition	-13.86%	-54.17%	-0.30%

4.2% of DeepVerge shares are owned by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are owned by institutional investors. 9.5% of DeepVerge shares are owned by insiders. Comparatively, 3.2% of Cambridge Cognition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Cambridge Cognition had 1 more articles in the media than DeepVerge. MarketBeat recorded 1 mentions for Cambridge Cognition and 0 mentions for DeepVerge. DeepVerge's average media sentiment score of 0.00 beat Cambridge Cognition's score of -0.10 indicating that DeepVerge is being referred to more favorably in the media.

Company	Overall Sentiment
DeepVerge	Neutral
Cambridge Cognition	Neutral

Summary

Cambridge Cognition beats DeepVerge on 9 of the 15 factors compared between the two stocks.

Get Cambridge Cognition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COG vs. The Competition

Export

Metric	Cambridge Cognition	Healthcare Technology Industry	Healthcare Sector	LON Exchange
Market Cap	£14.60M	£1.73B	£7.20B	£2.88B
Dividend Yield	N/A	4.69%	2.57%	6.26%
P/E Ratio	-6.94	20.48	274.36	366.74
Price / Sales	1.55	89.59	684.04	90,279.52
Price / Cash	4.31	31.71	77.01	27.89
Price / Book	3.72	6.07	10.47	6.34
Net Income	-£1.58M	-£18.66M	£3.48B	£5.89B
7 Day Performance	-2.66%	1.52%	0.94%	0.17%
1 Month Performance	-15.44%	3.54%	-0.03%	0.15%
1 Year Performance	-27.99%	-14.34%	18.28%	19.48%

Cambridge Cognition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COG Cambridge Cognition	1.3953 of 5 stars	GBX 27.06 -1.6%	GBX 56 +106.9%	-25.9%	£14.60M	£9.40M	N/A	74	Earnings Report Gap Up
RENX Renalytix	N/A	GBX 6.30 +12.5%	N/A	-17.1%	£27.53M	£3.30M	N/A	102	High Trading Volume
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+0.0%	£9.00M	£12.57M	N/A	74
FDBK Feedback	N/A	GBX 6.70 -2.2%	N/A	-45.6%	£2.94M	£849.62K	N/A	24	Gap Up
IQAI IQ-AI	N/A	GBX 0.80 flat	N/A	+0.0%	£1.77M	£538.19K	N/A	6	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:COG) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cambridge Cognition (COG) Competitors

COG vs. RENX, INHC, FDBK, IQAI, and DVRG

How does Cambridge Cognition compare to Renalytix?

Summary

How does Cambridge Cognition compare to Induction Healthcare Group?

Summary

How does Cambridge Cognition compare to Feedback?

Summary

How does Cambridge Cognition compare to IQ-AI?

Summary

How does Cambridge Cognition compare to DeepVerge?

Summary

Media Sentiment Over Time

COG vs. The Competition

Cambridge Cognition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cambridge Cognition (COG) Competitors

COG vs. RENX, INHC, FDBK, IQAI, and DVRG

How does Cambridge Cognition compare to Renalytix?

Which has stronger earnings and valuation, RENX or COG?

Does the media refer more to RENX or COG?

Do institutionals and insiders hold more shares of RENX or COG?

Which has more risk and volatility, RENX or COG?

Do analysts rate RENX or COG?

Is RENX or COG more profitable?

Summary

How does Cambridge Cognition compare to Induction Healthcare Group?

Do insiders and institutionals hold more shares of INHC or COG?

Which has higher valuation and earnings, INHC or COG?

Does the media refer more to INHC or COG?

Which has more volatility & risk, INHC or COG?

Do analysts prefer INHC or COG?

Is INHC or COG more profitable?

Summary

How does Cambridge Cognition compare to Feedback?

Which has more volatility & risk, COG or FDBK?

Which has better valuation & earnings, COG or FDBK?

Is COG or FDBK more profitable?

Do insiders & institutionals have more ownership in COG or FDBK?

Do analysts recommend COG or FDBK?

Does the media prefer COG or FDBK?

Summary

How does Cambridge Cognition compare to IQ-AI?

Which has better earnings & valuation, IQAI or COG?

Which has more risk & volatility, IQAI or COG?

Do analysts rate IQAI or COG?

Is IQAI or COG more profitable?

Do insiders and institutionals believe in IQAI or COG?

Does the media prefer IQAI or COG?

Summary

How does Cambridge Cognition compare to DeepVerge?

Do analysts recommend DVRG or COG?

Which has more volatility and risk, DVRG or COG?

Which has better earnings & valuation, DVRG or COG?

Is DVRG or COG more profitable?

Do institutionals & insiders have more ownership in DVRG or COG?

Does the media refer more to DVRG or COG?

Summary

Media Sentiment Over Time

COG vs. The Competition

Cambridge Cognition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools